Loading…
Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma
Adoptive transfer of cytotoxic T lymphocytes (CTLs) has been used as an immunotherapy in melanoma. However, the tumor homing and therapeutic efficacy of transferred CTLs against melanoma remain unsatisfactory. Interleukin-4 receptor (IL-4R) is commonly up-regulated in tumors including melanoma. Here...
Saved in:
Published in: | Biomaterials 2018-03, Vol.159, p.161-173 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3 |
container_end_page | 173 |
container_issue | |
container_start_page | 161 |
container_title | Biomaterials |
container_volume | 159 |
creator | Gunassekaran, Gowri Rangaswamy Hong, Chae-Moon Vadevoo, Sri Murugan Poongkavithai Chi, Lianhua Guruprasath, Padmanaban Ahn, Byung-Cheol Kim, Ha-Jeong Kang, Tae Heung Lee, Byungheon |
description | Adoptive transfer of cytotoxic T lymphocytes (CTLs) has been used as an immunotherapy in melanoma. However, the tumor homing and therapeutic efficacy of transferred CTLs against melanoma remain unsatisfactory. Interleukin-4 receptor (IL-4R) is commonly up-regulated in tumors including melanoma. Here, we studied whether IL-4R-targeted CTLs exhibit enhanced tumor homing and therapeutic efficacy against melanoma. CTLs isolated from mice bearing melanomas were non-genetically engineered with IL4RPep-1, an IL-4R-binding peptide, using a membrane anchor composed of dioleylphosphatidylethanolamine. Compared to control CTLs, IL-4R-targeted CTLs showed higher binding to melanoma cells and in vivo tumor homing. They also exerted a more rapid and robust effector response, including increased cytokine secretion and cytotoxicity against melanoma cells and enhanced reprogramming of M2-type macrophages to M1-type macrophages. Moreover, IL-4R-targeted CTLs efficiently inhibited melanoma growth and reversed the immunosuppressive tumor microenvironment. These results suggest that non-genetically engineered CTLs targeting IL-4R have potential as an adoptive T cell therapy against melanoma.
[Display omitted] |
doi_str_mv | 10.1016/j.biomaterials.2018.01.013 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989579615</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0142961218300188</els_id><sourcerecordid>1989579615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3</originalsourceid><addsrcrecordid>eNqNUU1rGzEUFCWlcdP-hSB6ymVdSbvaXeVWkn4ETHtJz0KW3q5lvJIjaUN87w_vc52UHgsPxEMz85gZQj5wtuSMtx-3y7WPkymQvNnlpWC8XzKOU78iC953fSUVk2dkwXgjKtVycU7e5rxluLNGvCHnQtUCIXxBfn2PoRohQPGWQhh9AJQNI40DtYcSS3zCj3tqYbfLtERaTBqh0LtV1dAEFvYlJiRuTLCAgHnCdROno4QJjpYNJLOH-Y_8MHhr7IGa0fiQC51gZwI6eUdeD-gE3j-_F-Tnl8_3N9-q1Y-vdzefVpWte1aqtWoE7x13nTRSrp00CrqBNbZ2bd-Aapx06N4pwwXrWN1yNojOqNpCK2Xj6gtyddLdp_gwQy568vnozASIc9Zc9Up2GJhE6PUJalPMOcGg98lPJh00Z_rYgt7qf1vQxxY04zg1ki-f78zrCdxf6kvsCLg9AQDdPnpIOlsPmKDzmGnRLvr_ufMbSp6hdQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989579615</pqid></control><display><type>article</type><title>Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Gunassekaran, Gowri Rangaswamy ; Hong, Chae-Moon ; Vadevoo, Sri Murugan Poongkavithai ; Chi, Lianhua ; Guruprasath, Padmanaban ; Ahn, Byung-Cheol ; Kim, Ha-Jeong ; Kang, Tae Heung ; Lee, Byungheon</creator><creatorcontrib>Gunassekaran, Gowri Rangaswamy ; Hong, Chae-Moon ; Vadevoo, Sri Murugan Poongkavithai ; Chi, Lianhua ; Guruprasath, Padmanaban ; Ahn, Byung-Cheol ; Kim, Ha-Jeong ; Kang, Tae Heung ; Lee, Byungheon</creatorcontrib><description>Adoptive transfer of cytotoxic T lymphocytes (CTLs) has been used as an immunotherapy in melanoma. However, the tumor homing and therapeutic efficacy of transferred CTLs against melanoma remain unsatisfactory. Interleukin-4 receptor (IL-4R) is commonly up-regulated in tumors including melanoma. Here, we studied whether IL-4R-targeted CTLs exhibit enhanced tumor homing and therapeutic efficacy against melanoma. CTLs isolated from mice bearing melanomas were non-genetically engineered with IL4RPep-1, an IL-4R-binding peptide, using a membrane anchor composed of dioleylphosphatidylethanolamine. Compared to control CTLs, IL-4R-targeted CTLs showed higher binding to melanoma cells and in vivo tumor homing. They also exerted a more rapid and robust effector response, including increased cytokine secretion and cytotoxicity against melanoma cells and enhanced reprogramming of M2-type macrophages to M1-type macrophages. Moreover, IL-4R-targeted CTLs efficiently inhibited melanoma growth and reversed the immunosuppressive tumor microenvironment. These results suggest that non-genetically engineered CTLs targeting IL-4R have potential as an adoptive T cell therapy against melanoma.
[Display omitted]</description><identifier>ISSN: 0142-9612</identifier><identifier>EISSN: 1878-5905</identifier><identifier>DOI: 10.1016/j.biomaterials.2018.01.013</identifier><identifier>PMID: 29329051</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adoptive T cell therapy ; Apoptosis - physiology ; Cell Line, Tumor ; Cell Proliferation - physiology ; Cytokines - metabolism ; Cytotoxic T lymphocytes ; Humans ; Immunotherapy - methods ; Interferon-gamma - metabolism ; Interleukin-4 receptor ; Melanoma ; Melanoma - metabolism ; Receptors, Interleukin-4 - metabolism ; T-Lymphocytes, Cytotoxic - metabolism</subject><ispartof>Biomaterials, 2018-03, Vol.159, p.161-173</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3</citedby><cites>FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29329051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gunassekaran, Gowri Rangaswamy</creatorcontrib><creatorcontrib>Hong, Chae-Moon</creatorcontrib><creatorcontrib>Vadevoo, Sri Murugan Poongkavithai</creatorcontrib><creatorcontrib>Chi, Lianhua</creatorcontrib><creatorcontrib>Guruprasath, Padmanaban</creatorcontrib><creatorcontrib>Ahn, Byung-Cheol</creatorcontrib><creatorcontrib>Kim, Ha-Jeong</creatorcontrib><creatorcontrib>Kang, Tae Heung</creatorcontrib><creatorcontrib>Lee, Byungheon</creatorcontrib><title>Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma</title><title>Biomaterials</title><addtitle>Biomaterials</addtitle><description>Adoptive transfer of cytotoxic T lymphocytes (CTLs) has been used as an immunotherapy in melanoma. However, the tumor homing and therapeutic efficacy of transferred CTLs against melanoma remain unsatisfactory. Interleukin-4 receptor (IL-4R) is commonly up-regulated in tumors including melanoma. Here, we studied whether IL-4R-targeted CTLs exhibit enhanced tumor homing and therapeutic efficacy against melanoma. CTLs isolated from mice bearing melanomas were non-genetically engineered with IL4RPep-1, an IL-4R-binding peptide, using a membrane anchor composed of dioleylphosphatidylethanolamine. Compared to control CTLs, IL-4R-targeted CTLs showed higher binding to melanoma cells and in vivo tumor homing. They also exerted a more rapid and robust effector response, including increased cytokine secretion and cytotoxicity against melanoma cells and enhanced reprogramming of M2-type macrophages to M1-type macrophages. Moreover, IL-4R-targeted CTLs efficiently inhibited melanoma growth and reversed the immunosuppressive tumor microenvironment. These results suggest that non-genetically engineered CTLs targeting IL-4R have potential as an adoptive T cell therapy against melanoma.
[Display omitted]</description><subject>Adoptive T cell therapy</subject><subject>Apoptosis - physiology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - physiology</subject><subject>Cytokines - metabolism</subject><subject>Cytotoxic T lymphocytes</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Interferon-gamma - metabolism</subject><subject>Interleukin-4 receptor</subject><subject>Melanoma</subject><subject>Melanoma - metabolism</subject><subject>Receptors, Interleukin-4 - metabolism</subject><subject>T-Lymphocytes, Cytotoxic - metabolism</subject><issn>0142-9612</issn><issn>1878-5905</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNUU1rGzEUFCWlcdP-hSB6ymVdSbvaXeVWkn4ETHtJz0KW3q5lvJIjaUN87w_vc52UHgsPxEMz85gZQj5wtuSMtx-3y7WPkymQvNnlpWC8XzKOU78iC953fSUVk2dkwXgjKtVycU7e5rxluLNGvCHnQtUCIXxBfn2PoRohQPGWQhh9AJQNI40DtYcSS3zCj3tqYbfLtERaTBqh0LtV1dAEFvYlJiRuTLCAgHnCdROno4QJjpYNJLOH-Y_8MHhr7IGa0fiQC51gZwI6eUdeD-gE3j-_F-Tnl8_3N9-q1Y-vdzefVpWte1aqtWoE7x13nTRSrp00CrqBNbZ2bd-Aapx06N4pwwXrWN1yNojOqNpCK2Xj6gtyddLdp_gwQy568vnozASIc9Zc9Up2GJhE6PUJalPMOcGg98lPJh00Z_rYgt7qf1vQxxY04zg1ki-f78zrCdxf6kvsCLg9AQDdPnpIOlsPmKDzmGnRLvr_ufMbSp6hdQ</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Gunassekaran, Gowri Rangaswamy</creator><creator>Hong, Chae-Moon</creator><creator>Vadevoo, Sri Murugan Poongkavithai</creator><creator>Chi, Lianhua</creator><creator>Guruprasath, Padmanaban</creator><creator>Ahn, Byung-Cheol</creator><creator>Kim, Ha-Jeong</creator><creator>Kang, Tae Heung</creator><creator>Lee, Byungheon</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201803</creationdate><title>Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma</title><author>Gunassekaran, Gowri Rangaswamy ; Hong, Chae-Moon ; Vadevoo, Sri Murugan Poongkavithai ; Chi, Lianhua ; Guruprasath, Padmanaban ; Ahn, Byung-Cheol ; Kim, Ha-Jeong ; Kang, Tae Heung ; Lee, Byungheon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adoptive T cell therapy</topic><topic>Apoptosis - physiology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - physiology</topic><topic>Cytokines - metabolism</topic><topic>Cytotoxic T lymphocytes</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Interferon-gamma - metabolism</topic><topic>Interleukin-4 receptor</topic><topic>Melanoma</topic><topic>Melanoma - metabolism</topic><topic>Receptors, Interleukin-4 - metabolism</topic><topic>T-Lymphocytes, Cytotoxic - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gunassekaran, Gowri Rangaswamy</creatorcontrib><creatorcontrib>Hong, Chae-Moon</creatorcontrib><creatorcontrib>Vadevoo, Sri Murugan Poongkavithai</creatorcontrib><creatorcontrib>Chi, Lianhua</creatorcontrib><creatorcontrib>Guruprasath, Padmanaban</creatorcontrib><creatorcontrib>Ahn, Byung-Cheol</creatorcontrib><creatorcontrib>Kim, Ha-Jeong</creatorcontrib><creatorcontrib>Kang, Tae Heung</creatorcontrib><creatorcontrib>Lee, Byungheon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomaterials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gunassekaran, Gowri Rangaswamy</au><au>Hong, Chae-Moon</au><au>Vadevoo, Sri Murugan Poongkavithai</au><au>Chi, Lianhua</au><au>Guruprasath, Padmanaban</au><au>Ahn, Byung-Cheol</au><au>Kim, Ha-Jeong</au><au>Kang, Tae Heung</au><au>Lee, Byungheon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma</atitle><jtitle>Biomaterials</jtitle><addtitle>Biomaterials</addtitle><date>2018-03</date><risdate>2018</risdate><volume>159</volume><spage>161</spage><epage>173</epage><pages>161-173</pages><issn>0142-9612</issn><eissn>1878-5905</eissn><abstract>Adoptive transfer of cytotoxic T lymphocytes (CTLs) has been used as an immunotherapy in melanoma. However, the tumor homing and therapeutic efficacy of transferred CTLs against melanoma remain unsatisfactory. Interleukin-4 receptor (IL-4R) is commonly up-regulated in tumors including melanoma. Here, we studied whether IL-4R-targeted CTLs exhibit enhanced tumor homing and therapeutic efficacy against melanoma. CTLs isolated from mice bearing melanomas were non-genetically engineered with IL4RPep-1, an IL-4R-binding peptide, using a membrane anchor composed of dioleylphosphatidylethanolamine. Compared to control CTLs, IL-4R-targeted CTLs showed higher binding to melanoma cells and in vivo tumor homing. They also exerted a more rapid and robust effector response, including increased cytokine secretion and cytotoxicity against melanoma cells and enhanced reprogramming of M2-type macrophages to M1-type macrophages. Moreover, IL-4R-targeted CTLs efficiently inhibited melanoma growth and reversed the immunosuppressive tumor microenvironment. These results suggest that non-genetically engineered CTLs targeting IL-4R have potential as an adoptive T cell therapy against melanoma.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29329051</pmid><doi>10.1016/j.biomaterials.2018.01.013</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0142-9612 |
ispartof | Biomaterials, 2018-03, Vol.159, p.161-173 |
issn | 0142-9612 1878-5905 |
language | eng |
recordid | cdi_proquest_miscellaneous_1989579615 |
source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list) |
subjects | Adoptive T cell therapy Apoptosis - physiology Cell Line, Tumor Cell Proliferation - physiology Cytokines - metabolism Cytotoxic T lymphocytes Humans Immunotherapy - methods Interferon-gamma - metabolism Interleukin-4 receptor Melanoma Melanoma - metabolism Receptors, Interleukin-4 - metabolism T-Lymphocytes, Cytotoxic - metabolism |
title | Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T10%3A56%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-genetic%20engineering%20of%20cytotoxic%20T%20cells%20to%20target%20IL-4%20receptor%20enhances%20tumor%20homing%20and%20therapeutic%20efficacy%20against%20melanoma&rft.jtitle=Biomaterials&rft.au=Gunassekaran,%20Gowri%20Rangaswamy&rft.date=2018-03&rft.volume=159&rft.spage=161&rft.epage=173&rft.pages=161-173&rft.issn=0142-9612&rft.eissn=1878-5905&rft_id=info:doi/10.1016/j.biomaterials.2018.01.013&rft_dat=%3Cproquest_cross%3E1989579615%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c380t-b94218d1d75a55bd5a9e7f04c3d684e94d5d878d9a120703610f27a93ce6554d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1989579615&rft_id=info:pmid/29329051&rfr_iscdi=true |